Navigation Links
Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
Date:6/22/2013

ry endpoints through 12 weeks include changes in fasting plasma glucose, hemoglobin A1c, body weight and measures of safety and tolerability. The study is fully enrolled with 240 patients with Type 2 diabetes.

Phase 2a Study Details
The randomized, double-blind, three-way crossover study compared the pharmacokinetics and pharmacodynamics of NewMet to generic metformin in patients with Type 2 diabetes. Twenty-four patients were randomized to receive twice-daily oral dosing of metformin HCl immediate release (1,000 mg), low dose NewMet (500 mg), and high dose NewMet (1,000 mg) for five days each separated by a one week washout. All treatments demonstrated similar reductions from baseline values in fasting plasma glucose (16-22 mg/dL, p<0.01 for all) and postprandial glucose (8%-12%, p<0.001 for all) despite a 45%-57% reduction in circulating metformin in the high and low dose NewMet arms, respectively. Gut hormones (GLP-1 and PYY) were increased similarly by more than 50% across all treatments. No safety concerns were noted for either NewMet or metformin.

Elcelyx Therapeutics' Posters at ADA: Links to Abstracts

Dissociation between metformin plasma exposure and its glucose-lowering effect: A novel gut-mediated mechanism of action

  • Date and Time: Sunday, June 23, 2013, 12:00 p.m. to 2:00 p.m. CT
  • Poster #, Category:  1087-P, 01-D Clinical Therapeutics/New Technology – Oral Agents

Delayed-release metformin may be suitable for use in diabetes patients
'/>"/>

SOURCE Elcelyx Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
2. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
3. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Report Details  New study shows ... What does the future hold for top companies ... new report shows you potential revenues to 2025, assessing ... 242-page report provides 185 tables, charts, and graphs. Discover ... future market prospects. Our new study lets you assess ...
(Date:3/27/2015)... 27, 2015 According to a ... Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), ... (AF, VT, WPW) - Global Forecasts to 2019 ", published ... reach around ~$4.73 Billion by 2019 with a CAGR ... 2019. Browse   90   ma ...
(Date:3/27/2015)... The International Myeloma Foundation (IMF) – improving ... toward prevention and a cure – today commended Representative ... resolution (H. Res. 174) that supports the designation of ... Awareness Month." Currently there are more than ... 110,000 new cases are diagnosed yearly, according to the ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... NxStage Medical, Inc. (Nasdaq: ... today announced that Joseph E. Turk, Jr., has been ... American operations.  Reporting to Jeffrey Burbank, Chief Executive Officer ... Company,s North American commercial teams across the Company,s three ...
... 2010 Endologix, Inc. (Nasdaq: ELGX ), ... today that Guido Neels, Managing Director at Essex Woodlands ... Essex Woodlands was the majority shareholder of Nellix Inc, ... transaction on December 13, 2010. In conjunction with the ...
Cached Medicine Technology:NxStage Names Joseph Turk President, North America 2Endologix Appoints Guido Neels to Its Board of Directors 2Endologix Appoints Guido Neels to Its Board of Directors 3
(Date:3/29/2015)... D.C. USA (PRWEB) March 29, 2015 ... Health Link platform provides basic health information ... the opportunity to discuss these challenges as well ... Afro Health Link addresses six medical conditions using ... encourage users to engage in conversations around them., ...
(Date:3/29/2015)... 2015 Final Cut Pro X ... Pixel Film Studios, entitled TranSports. , “TranSports is ... Final Cut Pro X,” said Christiana Austin, CEO of ... needed to effortlessly transition using this cool sports transition ... and uniquely styled transition pack for Final Cut Pro ...
(Date:3/29/2015)... Chicago, IL (PRWEB) March 29, 2015 ... W. Brickner, “and as we learn more about the ... , In March Homeostasis: Publius’ Go Endo-Cannabinoid Update ... homeostatic health, or endo-healing, is celebrated. Publius, of The ... four 2015 National Institutes of Health (PubMed) cannabinoid system ...
(Date:3/28/2015)... Coffee could not only perk you up ... gum disease, researchers have found. , They found that those ... contains antioxidants. Antioxidants fight gum disease. Does coffee, then, help ... Univ. Henry M. Goldman School of Dental Medicine explored in ... of the Journal of Periodontology. , “This is the first ...
(Date:3/28/2015)... March 28, 2015 "Necrorun" was featured ... takes a look at the latest and coolest applications ... Troohey, the host of NewsWatch and technology expert, conducted ... is an entertaining endless runner game with knights, nature, ... was released in 2009, according to Eurogamer. The popularity ...
Breaking Medicine News(10 mins):Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2
... Service Provider Grows 352%, ATLANTA, Sept. 30 ... business process outsourcing, today announced that it,has been ... fastest-growing privately held,companies in the US. The list ... segment of the economy - America,s independent-minded,entrepreneurs., ...
... CA, and NEW YORK, NY, September 30, 2008 ... world,s largest independent, non-profit biomedical research organizations, and ... only global non-profit organization focused solely on AIDS ... new research center dedicated exclusively to solving the ...
... 29 The Blue Cross and Blue,Shield Association (BCBSA) ... cultivating a workplace culture that supports the,careers of both ... best,places to hold a career in the healthcare industry., ... the "Best Places to,Launch a Career," while Modern Healthcare ...
... GORDONSVILLE, Va., Sept. 29 PBM Holdings, Inc., ... that its,presence in Canada is growing as more ... United States to Canadian parents. Now that,thousands of ... are no better than private-label formulas and there ...
... clinicians still using unproven treatments , , MONDAY, Sept. ... individual and group cognitive behavioral therapy helps reduce ... trauma symptoms, say U.S. researchers who reviewed ... However, despite the proven effectiveness of cognitive therapy, ...
... WASHINGTON, Sept. 29 Cephalon Inc. will,enter a criminal ... it,marketed three drugs for uses not approved by the ... The lawsuits were brought by former Cephalon employees ... Claims Act. The suits alleged that,Cephalon engaged in a ...
Cached Medicine News:Health News:RevenueMed Named to Inc. 5000 2Health News:Scripps Research Institute and IAVI launch world's first dedicated HIV neutralizing antibody center 2Health News:Scripps Research Institute and IAVI launch world's first dedicated HIV neutralizing antibody center 3Health News:Scripps Research Institute and IAVI launch world's first dedicated HIV neutralizing antibody center 4Health News:Blue Cross and Blue Shield Association Recognized by BusinessWeek, Modern Healthcare and AARP as a Top Workplace 2Health News:Blue Cross and Blue Shield Association Recognized by BusinessWeek, Modern Healthcare and AARP as a Top Workplace 3Health News:Blue Cross and Blue Shield Association Recognized by BusinessWeek, Modern Healthcare and AARP as a Top Workplace 4Health News:Canadian Brand-Name Infant Formulas No Better than Private-Label Formulas 2Health News:Cognitive Behavioral Therapy Best for Traumatized Youths 2Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 2Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 3Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 4Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 5
... The High-Mag 1.5x is ... membrane peeling in macular hole ... and macularepiretinal membrane removal, traditional ... warranting higher magnification. This lens ...
... Prism are designed for midperipherical ... for tractional retinal detachments (PDR, ... detachment. They can be used ... midperipheral laser applications. Direct image ...
The Chalam Mid Field lens can be used for air/gas exchange and has a bi-concave design to provide the widest field available in a direct image surgical lens. This lens was developed with K.V. Chalam,...
... 1.5x is specifically designed ... peeling in macular hole ... sheathotomy and macularepiretinal membrane ... and other situations warranting ...
Medicine Products: